萬泰生物(603392.SH)業績快報:2021年度淨利升197.83%至20.16億元
格隆匯2月14日丨萬泰生物(603392.SH)披露2021年度業績快報,報吿期內,公司實現營業收入57.50億元,同比增長144.25%;利潤總額23.21億元,同比增長203.59%;歸屬於上市公司股東的淨利潤20.16億元,同比增長197.83%;歸屬於上市公司股東的扣除非經常性損益的淨利潤19.40億元,同比增長214.48%。
影響經營業績的主要因素為公司二價宮頸癌疫苗繼續保持產銷兩旺,收入及利潤高速增長;因新冠肺炎疫情仍未得到有效控制,境外檢測需求大幅增加,公司新冠原料銷售和境外檢測試劑出口收入實現快速增長。
報吿期末,公司總資產70.47億元,較期初增長101.13%;歸屬於上市公司股東的所有者權益44.61億元,較期初增長74.69%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.